Sarah A Meyer1, Jean Ludovic Kambou2, Amanda Cohn3, James L Goodson4, Brendan Flannery5, Isaïe Medah6, Nancy Messonnier7, Ryan Novak8, Fabien Diomande9, Mamoudou H Djingarey10, Thomas A Clark11, Issaka Yameogo12, Amadou Fall13, Kathleen Wannemuehler14. 1. Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C25, Atlanta, GA 30333, United States; Epidemic Intelligence Service, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS E92, Atlanta, GA 30333, United States. Electronic address: smeyer@cdc.gov. 2. Direction de la Prévention par les Vaccinations, Burkina Faso Ministry of Health, 03 BP 7009 Ouagadougou, Burkina Faso. Electronic address: kambouludo@hotmail.com. 3. Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C25, Atlanta, GA 30333, United States. Electronic address: anc0@cdc.gov. 4. Global Immunizations Division, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS A04, Atlanta, GA 30333, United States. Electronic address: fez9@cdc.gov. 5. Global Immunizations Division, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS A04, Atlanta, GA 30333, United States. Electronic address: bif4@cdc.gov. 6. Direction de la Lutte contre la Maladie, Burkina Faso Ministry of Health, 03 BP 7009 Ouagadougou, Burkina Faso. Electronic address: isaiemedah@yahoo.fr. 7. Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C25, Atlanta, GA 30333, United States. Electronic address: nar5@cdc.gov. 8. Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C25, Atlanta, GA 30333, United States. Electronic address: bnk4@cdc.gov. 9. Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C25, Atlanta, GA 30333, United States. Electronic address: fed2@cdc.gov. 10. World Health Organization Intercountry Support Team for West Africa, 158 Avenue de l'Indépendance, 03 BP 7019 Ouagadougou, Burkina Faso. Electronic address: djingareyh@who.int. 11. Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C25, Atlanta, GA 30333, United States. Electronic address: tnc4@cdc.gov. 12. Direction de la Lutte contre la Maladie, Burkina Faso Ministry of Health, 03 BP 7009 Ouagadougou, Burkina Faso. Electronic address: yameogoissaka@yahoo.fr. 13. World Health Organization Intercountry Support Team for West Africa, 158 Avenue de l'Indépendance, 03 BP 7019 Ouagadougou, Burkina Faso. Electronic address: falla@who.int. 14. Global Immunizations Division, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS A04, Atlanta, GA 30333, United States. Electronic address: kpw9@cdc.gov.
Abstract
BACKGROUND: A new serogroup A meningococcal conjugate vaccine (PsA-TT, MenAfriVac™) has been developed to combat devastating serogroup A Neisseria meningitis (MenA) epidemics in Africa. A mass immunization campaign targeting 1-29 year olds was conducted in Burkina Faso in December 2010. Protection of subsequent infant cohorts will be necessary through either introduction of PsA-TT into the routine Expanded Programme on Immunization (EPI) or periodic repeat mass vaccination campaigns. OBJECTIVES: To inform future immunization policy for PsA-TT vaccination of infants through a comparison of PsA-TT campaign vaccination coverage and routine measles-containing vaccine (MCV) coverage in Burkina Faso. METHODS: A national survey was conducted in Burkina Faso during December 17-27, 2011 using stratified cluster sampling to assess PsA-TT vaccine coverage achieved by the 2010 nationwide immunization campaign among 2-30 year olds and routine MCV coverage among 12-23 month olds. Coverage estimates and 95% Confidence Intervals (CI) were calculated, reasons for non-vaccination and methods of campaign communication were described, and a multivariable analysis for factors associated with vaccination was conducted. RESULTS: National overall PsA-TT campaign coverage was 95.9% (95% CI: 95.0-96.7) with coverage greater than 90% all 13 regions of Burkina Faso. National overall routine MCV coverage was 92.5% (95% CI: 90.5-94.1), but ranged from 75.3% to 95.3% by region. The primary predictor for PsA-TT vaccination among all age groups was a head of household informed of the campaign. PsA-TT vaccination was more likely in residents of rural settings, whereas MCV vaccination was more likely in residents of urban settings. CONCLUSION: Overall national vaccination rates in Burkina Faso were similar for PsA-TT and MCV vaccine. The regions with MCV coverage below targets may be at risk for sub-optimal vaccination coverage if PsA-TT is introduced in EPI. These results highlight the need for assessments of routine vaccination coverage to guide PsA-TT immunization policy in meningitis belt countries. Published by Elsevier Ltd.
BACKGROUND: A new serogroup A meningococcal conjugate vaccine (PsA-TT, MenAfriVac™) has been developed to combat devastating serogroup A Neisseria meningitis (MenA) epidemics in Africa. A mass immunization campaign targeting 1-29 year olds was conducted in Burkina Faso in December 2010. Protection of subsequent infant cohorts will be necessary through either introduction of PsA-TT into the routine Expanded Programme on Immunization (EPI) or periodic repeat mass vaccination campaigns. OBJECTIVES: To inform future immunization policy for PsA-TT vaccination of infants through a comparison of PsA-TT campaign vaccination coverage and routine measles-containing vaccine (MCV) coverage in Burkina Faso. METHODS: A national survey was conducted in Burkina Faso during December 17-27, 2011 using stratified cluster sampling to assess PsA-TT vaccine coverage achieved by the 2010 nationwide immunization campaign among 2-30 year olds and routine MCV coverage among 12-23 month olds. Coverage estimates and 95% Confidence Intervals (CI) were calculated, reasons for non-vaccination and methods of campaign communication were described, and a multivariable analysis for factors associated with vaccination was conducted. RESULTS: National overall PsA-TT campaign coverage was 95.9% (95% CI: 95.0-96.7) with coverage greater than 90% all 13 regions of Burkina Faso. National overall routine MCV coverage was 92.5% (95% CI: 90.5-94.1), but ranged from 75.3% to 95.3% by region. The primary predictor for PsA-TT vaccination among all age groups was a head of household informed of the campaign. PsA-TT vaccination was more likely in residents of rural settings, whereas MCV vaccination was more likely in residents of urban settings. CONCLUSION: Overall national vaccination rates in Burkina Faso were similar for PsA-TT and MCV vaccine. The regions with MCV coverage below targets may be at risk for sub-optimal vaccination coverage if PsA-TT is introduced in EPI. These results highlight the need for assessments of routine vaccination coverage to guide PsA-TT immunization policy in meningitis belt countries. Published by Elsevier Ltd.
Authors: Paul A Kristiansen; Fabien Diomandé; Absatou Ky Ba; Idrissa Sanou; Abdoul-Salam Ouédraogo; Rasmata Ouédraogo; Lassana Sangaré; Denis Kandolo; Flavien Aké; Inger Marie Saga; Thomas A Clark; Lara Misegades; Stacey W Martin; Jennifer Dolan Thomas; Sylvestre R Tiendrebeogo; Musa Hassan-King; Mamoudou H Djingarey; Nancy E Messonnier; Marie-Pierre Préziosi; F Marc Laforce; Dominique A Caugant Journal: Clin Infect Dis Date: 2012-10-19 Impact factor: 9.079
Authors: Ryan T Novak; Jean Ludovic Kambou; Fabien Vk Diomandé; Tiga F Tarbangdo; Rasmata Ouédraogo-Traoré; Lassana Sangaré; Clement Lingani; Stacey W Martin; Cynthia Hatcher; Leonard W Mayer; F Marc Laforce; Fenella Avokey; Mamoudou H Djingarey; Nancy E Messonnier; Sylvestre R Tiendrébéogo; Thomas A Clark Journal: Lancet Infect Dis Date: 2012-07-18 Impact factor: 25.071
Authors: C A de Quadros; J M Olivé; B S Hersh; M A Strassburg; D A Henderson; D Brandling-Bennett; G A Alleyne Journal: JAMA Date: 1996-01-17 Impact factor: 56.272
Authors: Sara Tartof; Amanda Cohn; Félix Tarbangdo; Mamoudou H Djingarey; Nancy Messonnier; Thomas A Clark; Jean Ludovic Kambou; Ryan Novak; Fabien V K Diomandé; Isaïe Medah; Michael L Jackson Journal: PLoS One Date: 2013-05-09 Impact factor: 3.240
Authors: D M Daugla; J P Gami; K Gamougam; N Naibei; L Mbainadji; M Narbé; J Toralta; B Kodbesse; C Ngadoua; M E Coldiron; F Fermon; A-L Page; M H Djingarey; S Hugonnet; O B Harrison; L S Rebbetts; Y Tekletsion; E R Watkins; D Hill; D A Caugant; D Chandramohan; M Hassan-King; O Manigart; M Nascimento; A Woukeu; C Trotter; J M Stuart; McJ Maiden; B M Greenwood Journal: Lancet Date: 2013-09-12 Impact factor: 79.321
Authors: S M Niaz Arifin; Christoph Zimmer; Caroline Trotter; Anaïs Colombini; Fati Sidikou; F Marc LaForce; Ted Cohen; Reza Yaesoubi Journal: Med Decis Making Date: 2019-07-03 Impact factor: 2.583
Authors: Reza Yaesoubi; Caroline Trotter; Caroline Colijn; Maziar Yaesoubi; Anaïs Colombini; Stephen Resch; Paul A Kristiansen; F Marc LaForce; Ted Cohen Journal: PLoS Med Date: 2018-01-24 Impact factor: 11.069
Authors: Mamoudou H Djingarey; Fabien V K Diomandé; Rodrigue Barry; Denis Kandolo; Florence Shirehwa; Clement Lingani; Ryan T Novak; Carol Tevi-Benissan; William Perea; Marie-Pierre Preziosi; F Marc LaForce Journal: Clin Infect Dis Date: 2015-11-15 Impact factor: 9.079